Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bristol-Myers Squibb
Age
0–11
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
Confirmed HIV-1 infection diagnosed by protocol criteria
Screening HIV RNA level ≥1000 copies/mL
≥3 months to \<11 years of age at time of first treatment
Antiretroviral-naive or -experienced
At screening, all participants must have genotypic sensitivity to atazanavir and at least 2 nucleoside reverse transcriptase inhibitors (NRTIs), which must be approved for pediatric use at the local country.
Antiretroviral-experienced patients must also have documented phenotypic sensitivity at screening to atazanavir (Fold Change in susceptibility \<2.2) and to at least 2 NRTIs that are approved in their country
You may not be if
Experienced participants who received atazanavir or atazanavir/ritonavir at any time prior to study enrollment or who have a history of 2 or more protease inhibitor failures
Antiretroviral-naïve or -experienced HIV-1-infected patients with contraindication to study medications
Cardiac rhythm abnormalities
Need for tenofovir
Weight \<5 or ≥35kg
\>Grade 2 abnormality in aspartate transaminase/alanine transaminase levels
Coinfection with either hepatitis B or C virus
Any active Centers for Disease Control and Prevention Category C clinical condition
